Dr. Lindsay Rosenwald – The Success Story
Today Biotechnology Industry is a fast track. Dr. Lindsay Rosenwald has become a leading personality in this Industry. The activities are well-diversified. Dr. Lindsay Rosenwald contributed to the development of the Biotechnology Industry. The Portfolio Companies are engaged in the advancement of Drug research and development.
Another company of Dr. Lindsay Rosenwald is having network across the globe in the field of HealthCare Investment and Development. This company also gives guidance to new comers in this field and has become Role model to them. It is engaged in financial services and venture capital and also a Registered Broker-Dealer. At present this company accumulated funds nearly worth $950,000,000 since its birth in the year nineteen ninety nine.
Regarding his academic career Dr. Lindsay Rosenwald completed his graduate from Abington High School in Pennsylvania in the year nineteen seventy seven and after that he did graduation in medicine from Temple University School of medicine. After completion of internship at Abington Medical Hospital he carried on private medical practice for about two years. Later in 1986 he shifted to Wall Street. There he made use of his combined knowledge in the spheres of medicine and finance. At that time very few people had the combination of knowledge of both the disciplines. Dr. Lindsay Rosenwald’s combination of knowledge in both medicine and finance laid fast tracks that today kept him on fore front of success in the field of Biotechnology and Finance.
During his career as an Entrepreneur he has funded a number of world famous companies. After that the expansion was very fast and there was a great increase in the number of companies managed by him. All the companies have worked with the main object of financing to help the research and development and advanced research in the field of Biotechnology. Dr. Lindsay Rosenwald’s Group of Industries has made grand success in the Drug invention. One example in the connection is Cougar Biotechnology, one of his groups of companies, that has been engaged in examining its application in the treatment of prostate cancer. This company was purchased by Johnson and Johnson Company at a huge amount of one billion dollars.
Dr. Lindsay Rosenwald also established Rosenwald Foundation which is charitable foundation and is engaged in research and development in drugs and clinical research. He is also acting as Director and CEO in many numbers of private and public companies across the globe. He formulated and sold way a number of companies with FDA’s approval. Polarx was taken over by Cell Therapeutics and Myraid Pharmaceuticals purchased Javelin Pharmaceuticals and Enzymed Corporation was acquired by Albany Molecular. The secret of his success is acquisition of combined knowledge and experience in the fields of medicine and finance.
His investment portfolio speaks volumes about his vision orientation and forward thinking. His strong belief is that there will be a tremendous growth in the area of biotechnology in the coming twenty years. The rate at which the industry is going, it is sure that we will see a very good number of changes. According to Rosenwald, upcoming medical discoveries will come via small biotech businesses, which are concentrated in, on producing only a few products, as opposed to a huge biotech organization, which has many projects in work at once. He believes the two most pressing issues we encounter these days are heart disease and cancer.
Related posts:
Lindsay Rosenwald is the one person who is been giving his best efforts for the benefit of Bio technology. There are few people who are changing the world with their honest vision. Lindsay Rosenwald, is one such person who is with great vision and with passion towards developing life saving drugs for the man kind. I am really impressed to see his success story. His investment portfolio speaks volumes about his focus towards developing this wonderful industry.
I agree with the comments made so far about Lindsay Rosenwald. He is definitely an inspiration for the coming generation. Bio technology is going to be the future research area. Contributing to such an industry is a note worthy. Lindsay Rosenwald is definitely going to make good number of followers in the coming future.
I know Lindsay Rosenwald as a person. Rosenwald left his private practice in 1986 to go to Wall Street where he took on a position as a Physician / Analyst, a really exclusive position with just a few individuals doing it at the time. Even though some doubted if he could thrive in this position, he showed those that doubted him that he was extremely proficient at investments. He had a passion for improving venture capital open to the health care industry and that’s largely why he worked there. He received great respect in his brand new position, and although he missed his old private practice, he recognized this is where he actually belonged. He also worked for a private investment company, DH Blair Co as the Controlling Director of Finance, but left eventually to concentrate on a new endeavor.
Lindsay is one of the few people who changed the status quo in the biotechnology market by setting up various companies that are involved in clinical research and drug development.
Nice to know more about him
The person who thinks of the future of the bio-technology can be the foremost already named as Dr. Lindsay Rosenwald. Mounted at the highest point of the world by providing his services up to, the best whether in the form of the providing funds to the organizations that deals with the same as that which the his does or in the core field of research.The thing that speaks of the future mind scope of Lindsay is the trust which he has on the small biotehnology based companies which would further help to improve the increasingly filing cases of the heart diseases and the cancers.
I agree with the comments made so far about Lindsay Rosenwald. He is definitely an inspiration for the coming generation. Bio technology is going to be the future research area. Contributing to such an industry is a note worthy. Lindsay Rosenwald is definitely going to make good number of followers in the coming future.
[...] continued to mention how Dr. Lindsay Rosenwald established a private practice for two and a half years prior to coming to Wall Street as a [...]
this is the right person who is best eligible for the people who want to make out their career in this case and also he has become an brand to be an example is not an easy task but being a member of student of some other field even then he joined did something of his interest this itself shows how enjoyable i the lindsay’s work
Dr. Lindsay Rosenwald sits on the Board of Directors for the Republican Jewish Coalition. As a board member, his biography appears on the coalition’s website, http://www.rjchq.org. This biography details Dr. Lindsay Rosenwald’s current professional status as the senior managing director of a Capital Asset Management company, which he also co-founded. The company specializes in financing for the biotechnology field, which includes private equity, hedge funds, and venture capital.
As a member of the Wellness.com community, Dr. Lindsay Rosenwald’s credentials and current practice are displayed in his Wellness.com profile. He graduated from Temple University Medical School and is currently a general practitioner in New York City. Dr. Lindsay Rosenwald offers many services, including physical examinations, cholesterol testing, fitness programs, and skin biopsies.
Dr. Lindsay Rosenwald is an active member of the NyICECATS. The NyICECATS is a Jewish Orthodox youth hockey organization that includes an adult team. When Dr. Lindsay Rosenwald attended the third and fourth annual Captain’s Dinner in New York City on March 12th he was presented with gifts by Neil Herskowitz who is the Director of Manhattan Pharmaceuticals, Inc. The gifts included a Bauers 190. During the dinner, Dr. Lindsay Rosenwald spoke and said he was committed to playing hockey at the Piers for 25 more years. The celebration ended with the “Golden Balls” award ceremony.
The Huffington Post’s FundRace of 2008 reports Dr. Lindsay Rosenwald’s donation to the McCain Victory Committee, which amounted to $61,800.
Chelsea’s compound, has demonstrated superiority in terms of each safety and efficacy
in excess of Methotrexate, the current remedy standard for RA, which continues to
be identified to elevate liver enzymes in quite a few people in addition to Lindsay
Rosenwald. Extremely important Capital licensed these technologies on the University
of South Alabama and assembled a world-class management team to help optimize its
formulation and advance the development of this and other compounds.
A different academic license from Important is a profile of organic arsenic trioxide
compounds licensed through the MD Anderson Cancer Center. This FDA approved
compound progressed from IND to NDA in about 30 months and this could be the
quickest regulatory approval inside FDA historical past. Trisenox, an inorganic
alternative of arsenic trioxide, which can item creates cardiac abnormalities at large
doses. By contrast using the inorganic edition, natural and organic arsenic trioxide does
not display evidence of these problems, even when applied at doses dual ten periods
larger than Trisenox. To leverage that advantage, Dr. Lindsay Rosenwald founded
Ziopharm Oncology to advance this organic and natural arsenic compound, ZIO-
101, to deal with cancers, which include solid tumors, exactly where mega dosing has
verified efficient. Ziopharm Oncology, subsequently has in-licensed and is developing several other anti-cancer agents.
Another Vital profile corporation, founded and managed by Lindsay Rosenwald
M.D., is Keryx Bio pharmaceuticals. It really is creating a compound termed Sulonex,
which can be an oral treatment for diabetic nephropathy. It was licensed in the Alfa
Wassermann Group, a privately held pharmaceutical firm in Bologna, Italy. If authorized,
Sulonex will probably be marketed to 15 million persons diagnosed with Kind two
diabetes as well since the one to 2 million affected individuals with Type 1 diabetes.
Extremely important Bio Sciences, LLC, a global pharmaceutical development and
wellness care investment corporation, was founded and managed by Dr. Lindsay A.
Rosenwald in 19th centuries. The organization facilitates drug development, scientific
assistance and dedicates itself to locating and creating novel therapeutic medicines with
big potential. By assessing promising drug candidates throughout the world, Important
has been able to create, nurture, and help far more than 40 lifestyle sciences corporations,
academic centers, biotechnology and pharmaceutical firms over the past 19 years, which
includes 20 inside the final 48 months. Present Portfolio Corporations have more than 40
solution candidates advancing through clinical trials.
Special method to bio tech purchase: Business and solution growth are just two
pieces inside Very important puzzle. An affiliate of extremely important Bio
Sciences – with the Lindsay Rosenwald Bio Cash, Inc., is a FINRA
registered broker-dealer that, amongst other actions, raises capital with the Very
important Profile Companies. It raised over $1 billion for the Portfolio Corporations;
a number of times that sum have become raised for Vital Businesses by other entities.
Dr. Lindsay Rosenwald is among the most elite people in biotechnology financing field.
He is very seasoned professional in this field. Known for his financial genius, He continuously strives for better. During these twenty active years, he funded many new companies helping them establishing in the biotechnology field. His has a deep insight in financial management and his vision is really impressive. His clients are one of the leading US pharmaceutical and biotech companies. Apart from his versatility he is a warm hearted generous man, who likes to do his bit in various noble causes. This kind of qualities and character he’s got, he is set to become an icon in the industry.
Dr. Lindsay Rosenwald a venture capitalist and is a hedge fund manager who is based at New York and is famous for his expertise in the disciplines of finances and medicine. He is a man of many achievements to his credit. He started so many companies relating to biotechnology and is a partner in many firms of great reputation. He is also the president of Rosenwald foundation named after him. This charitable trust works from outside New York. Dr. Lindsay Rosenwald contributes a lot by continuing to fund the research activities in biotechnology and other related fields through this foundation and is of great help in advancing the technology to greater heights.
Dr. Lindsay Rosenwald is chairman and cofounder of companies that look after asset management, portfolio management and investment management. Dr. Lindsay Rosenwald is also Director of many public and private biotechnology companies. He is also a member of Columbia Presbyterian Health services advisory council.
All the companies in which Dr. Lindsay Rosenwald is a member or a founder have been pioneers in research work and came out with excellent molecules that stood as milestones in biotechnology and pharmaceuticals. Drugs that are used to cure H1N1 virus, Schizophrenia, Rheumatoid arthritis, cancer and leukemia are a few to name that were discoveries of the portfolio companies that work under the visionary leadership of Dr. Lindsay Rosenwald.
Dr. Lindsay Rosenwald has many achievements to his credit. He stands first in many remarkable events and advancements that took place in the field of biotechnology. In one word one can say that he is a pioneer in biotechnology field. He introduced the first anti obesity drug in to American market. He founded the first publicly traded gene therapy company. He was also the founder of a company which stood first as publicly traded stem cell company. Even his company was first in coming out with cancer vaccine therapy.
Dr. Lindsay Rosenwald did his major in finances from Pennsylvania University in 1977 and went on to do his medicine at Temple University school of medicine. He did internship at Abington hospital. He also did some private medical practice until 1986. He relocated himself to Wall Street and worked as a physician analyst. He was the first among the physician analysts in the country then. He proved himself as a great entrepreneur in biotechnology in the past twenty years. It is one of the noteworthy investments he made in the field of biotechnology. Dr. Lindsay Rosenwald raised about one billion dollars fund for research and development in the field of biotechnology and drug development through this company. It is his vision and capability that made him stood first in many things in the fields of finances and medicine.
Dr. Lindsay Rosenwald utilized his vast knowledge and experience in medicine and finances to enrich the pharmaceutical industry with new molecules. He made so many investments in drug development that have become relevant and indispensable in the modern medicine. His every achievement has been great leap forward in the biotechnology and investments. His contribution to the medicine is remarkable and cannot be achieved by anybody.
You really allow it to be seem really easy with your business presentation but My spouse and i find this topic being really an issue that I think I’d personally never recognize. It seems too complicated and extremely broad for me personally. I am looking forward for your next publish, I will attempt to get the hang of it!
J&J’s abiraterone shows survival improvement by about four months
The results from a Phase III clinical trial demonstrated that an oral androgen synthesized inhibitor by Johnson & Johnson, abiraterone acetate, improves the survival rate by about 4 months if compared with the placebo effect in patients suffering from prostate cancer aggravated by visceral metastases.
The interim analysis of the COU-AA-301 study of 1,195 patients presented at the 35th annual congress of European Society for Medical Oncology (ESMO) in Milan, Italy, showed a great survival rate and good safety profile of abiraterone.
The company revealed its COU-AA-301 clinical trial along with the recommendations of its Independent Data Monitoring Committee, which suggested that the patients taking placebo should be also treated with abiraterone acetate combined with low doses of prednisone.
Originally designed by Prof. Mike Jarman and other personnel of the Cancer Research Therapeutics Unit at Britain’s Institute of Cancer Research (ICR) and funded by Dr. Lindsay Rosenwald and his company, abiraterone is going to be filed for approval in the US and Europe by the end of 2010. Being one of the leading investors in the biotechnology sector, Dr. Rosenwald and his portfolio companies promote the development of promising discoveries and their commercialization. As one of the most promising inventions for the treatment of prostate cancer, abiraterone will be applied by Johnson & Johnson for approval in the rest of the world according to local regulations.
Once approved, abiraterone acetate will be distributed by Lindsay Rosenwald’s portfolio company, Centocor Ortho Biotech Inc, in the US. The rest of the world will see the drug thanks to Janssen Pharmaceutical Companies.
In 2009, abiraterone was acquired along with Lindsay Rosenwald’s portfolio company, Cougar Biotechnology, for US $ 970 million, which in its turn had licensed abiraterone acetate from the BTG life sciences company in the UK.
Improved survival in 36%
The COU-AA-301 trial Phase III was made in 13 countries and included patients suffering from prostate cancer aggravated by visceral metastases. A total of 797 patients took abiraterone acetate (in the dose of 1,000 mg a day) in a combination with prednisone or prednisolone (5 mg twice a day) and 398 patients took placebo with prednisone or prednisolone. The interim trial demonstrated that the patients treated with abiraterone acetate were less prone to fatal outcome, while the placebo group had a 36% increase in death rate. The prostate-specific antigen (PSA) progression time increased from 6.6 months to 10.2 months in the placebo group, while the abiraterone patients had significant improvements.
38% of patients undergoing the abiraterone treatment achieved total PSA response, while only 10% achieved the same in the prednisone and placebo group.
According to Dr. Lindsay Rosenwald and Dr. Johann de Bono, who were among the lead COU-AA-301 investigators, abiraterone acetate has all the potential to meet the needs of the biomedical sector and is extremely important to the patients with prostate cancer as well as their families.
The results were very promising because men with metastatic advanced prostate cancer have very few treatment options and poor results.
New treatment possibilities
Andrew Paramore, one of the leading Datamonitor analysts, believes that the results of the abiraterone treatment are striking, since very few drugs have been as effective as abiraterone acetate. However, Paramore says that choosing the drug for individual patients may be “a difficult task as two other drugs, Jevtana (carbazitaxel; Sanofi-Aventis) and Provenge (sipuleucel-T; Dendreon), have also shown a survival advantage, albeit in different subsets of patients”.
Now there are two possible treatment directions according to Paramore: the combination of the new drugs with each other or with other existing and already approved drugs. This will be done to increase the possible survival benefits as well as to improve the quality of life in patients with prostate cancer.